Busulfan-cyclophosphamide versus total body irradiation–cyclophosphamide as preparative regimen before allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia: What have we learned?-Reference-Cited by-同舟云学术

Busulfan-cyclophosphamide versus total body irradiation–cyclophosphamide as preparative regimen before allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia: What have we learned?

Published:2003-12 Issue:12 Volume:31 Page:1182-1186
ISSN:0301-472X
Container-title:Experimental Hematology
language:en
Short-container-title:Experimental Hematology

Author:

Ferry Christèle,Socié Gérard

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Genetics,Hematology,Molecular Biology

Reference38 articles.

1. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation;Thomas;Blood,1977

2. Marrow transplantation for acute nonlymphoblastic leukemia in first remission;Thomas;N Engl J Med,1979

3. Busulfan (Bu) and cyclophosphamide (Cy) for marrow transplantation;Santos;Bone Marrow Transplant,1989

4. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide;Santos;N Engl J Med,1983

5. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen;Tutschka;Blood,1987

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Feasibility of intravenous vitamin C supplementation in allogeneic hematopoietic cell transplant recipients;eJHaem;2024-08-27

2. Complications of total-body irradiation in allogeneic bone marrow transplantation: A review article;Iranian Journal of Pediatric Hematology & Oncology;2024-04-05

3. INTRAVENOUS VITAMIN C SUPPLEMENTATION IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: SALUTARY IMPACT ON CLINICAL OUTCOMES;2023-10-25

4. Stem Cell Transplant for Acute Myeloid Leukemia;Basics of Hematopoietic Stem Cell Transplant;2023

5. MicroRNAs: Regulatory Biomarkers in Acute Myeloid Leukemia and Graft Versus Host Disease;Clinical Laboratory;2022